PCOS at a glance

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder very common among women of reproductive age. Patients may experience infrequent or prolonged menstrual periods, hirsutism, obesity, infertility, and ovarian enlargement, or excess male hormone (androgen) levels.

PCOS often disrupts a woman’s menstrual cycles, making it harder for these patients to get pregnant. Lifestyle modifications are the first treatments doctors recommend for PCOS, followed by pharmacological treatments such as clomiphene citrate or letrozole, to restart ovulation. These treatments are unfortunately not always effective, and further options bear significant costs, challenges and risks.

Polycystic Ovaries
AblaCare Procedure
More Natural. Less Medicalized.

At AblaCare, we believe that all women with PCOS should have a natural pregnancy experience. Since 2017, we have been working on developing an innovative solution, aiming to restore ovulation in patients through a simple, one-time, durable, minimally invasive treatment. The Procedure can be performed in a clinic setting, without General Anesthesia, using the same minimally invasive access commonly used by fertility physicians for IVF.

More Natural. Less Medicalized.

At AblaCare, we believe that all women with PCOS should have a natural pregnancy experience. Since 2017, we have been working on developing an innovative solution, aiming to restore ovulation in patients through a simple, one-time, durable, minimally invasive treatment. The Procedure can be performed in a clinic setting, without General Anesthesia, using the same minimally invasive access commonly used by fertility physicians for IVF.

Learn About Our Ongoing Clinical Trial

Our First-In-Woman feasibility Trial, ULTRA, is studying the safety and effectiveness of the AblaCare Procedure, in women with PCOS-infertility.

Patients with the following criteria may qualify to participate in the study:
- Adult patient diagnosed with PCOS
- Having failed first-line pharmacological treatment (clomiphene citrate, metformin, letrozole)

This multicenter, prospective trial is ongoing in 3 European geographies: France, Belgium, and the UK.

CAUTION: Investigational device, not currently available for sale.